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Abstract
Background: Prostate cancer metastasizes to regional lymph nodes and distant sites but the roles
of lymphatic and hematogenous pathways in metastasis are not fully understood.
Methods: We studied the roles of VEGF-C and VEGFR3 in prostate cancer metastasis by blocking
VEGFR3 using intravenous adenovirus-delivered VEGFR3-Ig fusion protein (VEGFR3-Ig) and by
ectopic expression of VEGF-C in PC-3 prostate tumors in nude mice.
Results: VEGFR3-Ig decreased the density of lymphatic capillaries in orthotopic PC-3 tumors (p <
0.05) and inhibited metastasis to iliac and sacral lymph nodes. In addition, tumor volumes were
smaller in the VEGFR3-Ig-treated group compared with the control group (p < 0.05). Transfection
of PC-3 cells with the VEGF-C gene led to a high level of 29/31 kD VEGF-C expression in PC-3
cells. The size of orthotopic and subcutaneous PC-3/VEGF-C tumors was significantly greater than
that of PC-3/mock tumors (both p < 0.001). Interestingly, while most orthotopic PC-3 and PC-3/
mock tumors grown for 4 weeks metastasized to prostate-draining lymph nodes, orthotopic PC-
3/VEGF-C tumors primarily metastasized to the lungs. PC-3/VEGF-C tumors showed highly
angiogenic morphology with an increased density of blood capillaries compared with PC-3/mock
tumors (p < 0.001).
Conclusion: The data suggest that even though VEGF-C/VEGFR3 pathway is primarily required
for lymphangiogenesis and lymphatic metastasis, an increased level of VEGF-C can also stimulate
angiogenesis, which is associated with growth of orthotopic prostate tumors and a switch from a
primary pattern of lymph node metastasis to an increased proportion of metastases at distant sites.
Background
A high proportion of prostate cancer patients have meta-
static disease, which causes high morbidity and mortality.
Tumor spread takes place primarily via lymphatic vessels,
which leads to early metastases in prostate-draining iliac
and sacral lymph nodes [1]. In advanced prostate cancer,
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tumors commonly metastasize to bone and other distant
sites presumably via angiogenic routes [2,3]. The mecha-
nisms causing invasive and metastatic prostate cancer are
still largely unknown. The interactions of lymphang-
iogenic and angiogenic pathways in the development of
distant metastases of prostate cancer are not fully under-
stood either. Metastasis in regional lymph nodes is associ-
ated with later appearance of bone metastases and a poor
prognosis of prostate cancer [4], but it is not known
whether spreading to distant sites occurs via regional
lymph nodes or directly via hematogenous routes [5].
Vascular endothelial growth factor C (VEGF-C) and its
receptors VEGFR3 and VEGFR2 have a central role in reg-
ulation of the development and function of the lymphatic
system as well as in tumor lymphangiogenesis. VEGF-C
induces lymphatic endothelial cell proliferation, survival
and migration in vitro [6,7]. It is a dimeric glycoprotein,
which binds and activates VEGF receptor tyrosine kinases
[8]. VEGF-C was first cloned from human prostate cancer
cell line (PC-3 cells) as a ligand for lymphangiogenic
receptor (VEGFR3) and angiogenic receptor (VEGFR2)
[9]. It is synthesized intracellularly as a 58 kD propeptide,
which undergoes proteolytic cleavage, and leads to 29 and
31 kD polypeptides, which are rapidly secreted and bind
VEGFR3 in particular with high affinity [6]. Additional
processing results in 21 kD VEGF-C, which binds both
VEGFR2 and VEGFR3 [6].
Peritumoral lymphangiogenesis enables tumor cell dis-
semination to lymphatic vessels. VEGF-C is overexpressed
in various human cancers including breast cancer [10-12]
and prostate cancer [13-16]. In experimental models,
tumor cells that overexpress VEGF-C induce peritumoral
lymphangiogenesis and tumor cell invasion to lymphatic
vessels [17-21]. However, conflicting data of this has been
reported in other studies suggesting that intratumoral
lymphatic vessels may not be functional or that peripheral
lymphatics may not function properly, which questions
the role of lymphangiogenesis in primary tumor cell dis-
semination [22,23]. The lymphangiogenic effects of
VEGF-C can be blocked by VEGFR3 inactivation [24-26].
Without VEGF-C or VEGFR3, lymphatic endothelial cells
are not able to form sprouting capillaries. In VEGF-C -/-
mice, the sprouting of lymphatic vessels can be rescued by
adding VEGF-C or VEGF-D (another lymphangiogenic
growth factor that binds VEGFR3) but not VEGF, which
indicates that the lymphangiogenic effects of VEGF-C are
mediated primarily through VEGFR3 [27]. Like VEGF-C,
VEGFR3 is upregulated in vascular endothelial cells in
pathological conditions such as solid tumors [25,28-31].
Regulation of VEGF-C and VEGFR3 in prostate cancer
metastasis was studied using orthotopic PC-3 prostate
tumors, which naturally express VEGF-C. Orthotopic PC-
3 tumors invade spontaneously to prostate-draining
lymph nodes, but dissemination to distant sites such as
bone, lung and liver occurs more slowly and less fre-
quently [32]. We studied the effect of blockade of VEGFR3
on PC-3 tumor growth and metastasis by using adenoviral
delivery of a VEGFR3 Ig fusion protein (VEGFR3-Ig),
which functions as a decoy receptor for VEGFR3. Further-
more, we studied the effect of a high level of VEGF-C on
growth, angiogenesis, lymphangiogenesis and metastasis
in orthotopic PC-3 prostate tumors, expressing ectopic
VEGF-C.
Methods
Cell culture and transfection
The human hormone-resistant prostate cancer cell line
PC-3 was obtained from the American Tissue Type Cul-
ture Collection (Rockville, MD, USA) and cultured in
DMEM supplemented (10%) with heat inactivated fetal
bovine serum, iFBS. At near confluence, cells were har-
vested in trypsin/EDTA solution (Biochrom AG, Ger-
many), washed with culture medium and finally
suspended at a concentration of 1 × 106/100 L in sterile
PBS for subcutaneous inoculation. For orthotopic inocu-
lation, cells were suspended at a concentration of 5 × 105/
20 L in a sterile dye solution consisting of PBS (Bio-
chrom AG, Germany) with green food color 33022 (5 g/
mL; Roberts Oy, Finland) [32,33]. The cells were kept on
ice until used for inoculation.
The expression vector pcDNA3.1(+) (Invitrogen, CA,
USA) containing human full-length VEGF-C cDNA [9] in
an ECORI site and an empty pcDNA3.1(+) vector (mock)
were used. Plasmids (2 g/well on a six-well plate) were
transfected into PC-3 cells using Lipofectamine (Invitro-
gen, CA, U.S.A) according to the manufacturer's instruc-
tions. Twenty-four hours after transfection, the cells were
transferred to selection medium containing neomycin
(G418 500 g/mL) for three weeks. Isolated colonies were
cloned. Cell clones were characterized by Northern and
Western blotting. Several VEGF-C positive clones were
obtained and one VEGF-C overexpressing clone (clone 1,
later called PC-3/VEGF-C) and one control clone (PC-3/
mock) where selected for in vivo studies.
RNA isolation and Northern blot analysis
Total RNA was extracted from PC-3/VEGF-C and PC-3/
mock cells using the guanidinium isothiocyanate method
[34]. Subsequently, 20 g of RNA was separated by elec-
trophoresis, stained with ethidium bromide and blotted
on GeneScreen Plus nylon membrane (NEN Research
Products, Boston, MA), using standard conditions sug-
gested by the manufacturer. A cDNA insert [9] of human
VEGF-C was [32P]-dCTP-labeled by the random priming
method (Ready-to-go DNA labeling Beads, Amersham
Pharmacia Biotech, Piscataway, NJ). Hybridization andBMC Cancer 2009, 9:362 http://www.biomedcentral.com/1471-2407/9/362
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exposure to X-ray film were carried out using conditions
suggested by the manufacturer.
Western blot analysis and enzyme-linked immunosorbent 
assay (ELISA) analysis
Serum-free DMEM conditioned by PC-3/VEGF-C and PC-
3/mock cells was harvested from the cultures. Heparin-
binding proteins were isolated from the supernatant with
100 L of heparin-sepharose (1:1 slurry; Amersham Phar-
macia Biotech, Piscataway, NJ, USA) overnight at 4°C.
Heparin-sepharose beads were sedimented by centrifuga-
tion and washed three times with 20 mM Tris-HCl, pH
7.4, 300 mM NaCl. Heparin-sepharose-bound proteins
conditioned by 3 × 106 cells were extracted by 5 min incu-
bation in Laemmli sample buffer at 95°C and separated
by gel electrophoresis (SDS-PAGE). After collecting the
conditioned media, also the cells were lysed to Laemmli
buffer and separated on gel similarly. After transfer to
nitrocellulose membrane (Bio-Rad), VEGF-C (from con-
ditioned media) or -actin (from cell lysates) was detected
using a 1:500 dilution of a rabbit polyclonal anti-human
VEGF-C antibody (Abcam, UK) or 1:2000 mouse mono-
clonal anti--actin antibody (Sigma, St Louis, MO).
Horseradish peroxidase-labeled anti-rabbit or anti mouse-
IgG (Jackson Immunoresearch Laboratories Inc, USA) was
used as a secondary antibody at 1:5000 dilutions. Protein
bands were visualized using the ECL chemiluminescence
detection system (Amersham Corp., Sweden) [19]. VEGF-
C protein concentrations from cell lysates and 24 h condi-
tioned media of cell clones were further quantified by
ELISA (Bender MedSystems, Vienna, Austria) according to
the manufacturer's instructions. Data was expressed as
VEGF-C protein concentration (ng/mL) corresponding to
106 cells.
Cancer cell inoculation into nude mice
Eight-week-old male athymic nu/nu mice (Harlan, Ger-
many) were used to produce orthotopic and subcutane-
ous prostate tumors. The animal experiments were carried
out according to the European Convention for the Protec-
tion of Vertebrate Animals used for Experimental and
other Scientific Purposes, Statutes 1076/85 §and 1360/90
of the Animal Protection Law in Finland and EU Directive
86/609. The experimental procedures were reviewed by
the local Ethics Committee on Animal Experimentation at
the University of Turku and approved by the local Provin-
cial State Office of Western Finland.
Experiment I was performed to study the effects of VEGFR3
blockade on prostate tumor growth. For this, mice were
randomized according to the weight into two groups (22
and 23 mice with VEGFR3-Ig and lacZ-Ig, respectively). 30
minutes before inoculation of tumor cells, an analgesic
drug (Temgesic, 0.3 g/g, Schering-Plough Europe, Bel-
gium) was injected subcutaneously. The mice were anes-
thetized by means of isofluran inhalation (1.5 - 3%, air
flow 200 mL/min, Univentor 400 anesthesia unit, Zejtun,
Malta) and placed in a supine position under a sterile
cover. An incision was made three mm above the pubic
symphysis and the bladder and seminal vesicles were care-
fully lifted to expose the dorsal prostate. Subsequently, 5
× 105 PC-3 cells with green dye were slowly inoculated
into the prostate. If leakage of cell suspension with green
dye was observed in the peritoneal cavity or urethra/blad-
der, the mouse was not included in the experiment
[32,33].
Experiment II was performed in order to study the effects
of ectopic overexpression of VEGFR3 ligand, VEGF-C, on
prostate tumor growth. First, the tumorigenicity of PC-3/
VEGF-C cells was studied by means of subcutaneous inoc-
ulation. For this, mice were randomized according to
weight into two groups (8 and 12 mice with PC-3/VEGF-
C and PC-3/mock, respectively). Tumor cell suspension
was inoculated subcutaneously at the back of the neck.
After inoculation, tumors were measured twice a week
and the volume was calculated according to formula (/
6)(d1 × d2)3/2, where d1 and d2 are perpendicular tumor
diameters. To further study the effects of VEGF-C overex-
pression, the PC-3/VEGF-C cells were orthotopically inoc-
ulated into the prostates of nude mice as described above.
For this, mice were randomized according to weight into
two groups (n = 33 and 28, PC-3/VEGF-C and PC-3/mock,
respectively).
Next, we studied if we can block the VEGFR3 pathway in
VEGF-C overexpressing orthotopic tumors. Mice were
divided into two groups according to the weight and were
injected with fusion proteins (12 and 8 mice with
VEGFR3-Ig and lacZ-Ig, respectively) five minutes before
orthotopic inoculation of PC-3/VEGF-C cells.
In vivo delivery of VEGFR3-Ig by adenoviral vectors
Recombinant adenoviruses (1.2 × 108 pfu per mouse [35],
a kind gift from Professor Seppo Ylä-Herttuala) [36]
expressing the VEGFR3-Ig fusion protein (VEGFR-3Ig) or
-galactosidase (lacZ) as a control were administered via
tail vein 5 minutes before orthotopic PC-3 or PC-3/VEGF-
C cell inoculation.
Histology and histomorphometry
Mice were sacrificed 4 weeks after subcutaneous or ortho-
topic inoculation of tumor cells. Subcutaneous tumor
diameters were measured and tumors were removed. The
prostates of orthotopic prostate tumor-bearing mice were
exposed and prostate/tumor volume was calculated by
means of the formula (d1 × d2 × d3)/6 [37]. The prostate,
the lungs and the regional prostate-draining lymph nodes
(iliac and sacral) were macroscopically examined for the
occurrence of tumors and subsequently collected for his-BMC Cancer 2009, 9:362 http://www.biomedcentral.com/1471-2407/9/362
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tology. Immediately after removal, tissue samples were
immersed in 4% neutral-buffered formalin. After two to
three days, the samples were transferred to 70% EtOH and
stored until processed further. All samples were embed-
ded in paraffin, cut through to five m thick sections and
stained with hematoxylin and eosin (H&E) using stand-
ard techniques. All samples were blind-evaluated for
metastasis by two independent analyzers.
The iliac and sacral lymph nodes were cut through and 8
to 10 sections/lymph node at 200 m intervals from every
tumor-bearing mice were analyzed. The relative area of
tumor metastasis in lymph nodes was determined from
H&E-stained sections by means of an analysis software
(AxioVision 4.3, Carl Zeiss Microimaging GmbH,
Oberkochen, Germany). The results were expressed as
percentage of the total area of the lymph node.
Immunohistochemistry
Formalin-fixed, paraffin-embedded sections of prostate
and lymph nodes were used for immunohistochemical
studies. Five-m sections were deparaffinized in xylene
and rehydrated in a descending series of ethanol (100 -
70%). Endogenous peroxidase activity was blocked with
3% hydrogen peroxidase for 30 min at room temperature.
Sections were incubated in humid chambers with a mouse
LYVE-1 (a kind gift from Dr. David Jackson [38]), CD34
(Santa Cruz, USA), VEGFR3 (a kind gift from Professor
Kari Alitalo [39]) and VEGFR2 (R&D, UK) antibodies o/n
at 4°C. The samples were treated with biotin-labeled goat
anti-mouse (Vector, Burlingame, USA), a biotin-labeled
rabbit anti-rat (DAKO, Denmark) or biotin-labeled rabbit
anti-mouse secondary antibodies, according to the nature
of the primary antibodies. Immunoperoxidase staining
was performed using an ABC kit (Vector Laboratories, CA,
USA). The slides were stained with diaminobenzidine
(DAB) and counterstained with Meyer's hematoxyline.
Known positive samples from every tumor and negative
controls (sections of every sample stained without the pri-
mary antibody) were used to verify the specificity of stain-
ing. Vascularization was determined as the density of the
CD34-, m-LYVE-1-, VEGFR2- and VEGFR3-positive ves-
sels. Vessels were determined from the three representive,
non-overlapping fields from one section of each sample
by drawing lines following stained vessels [32] and meas-
uring the density using AxioVision 4.3 software (Carl Zeiss
Microimaging GmbH, Oberkochen, Germany). The
results were blind-tested by two independent analyzers.
Statistics
Results were expressed as mean value ± SEM. Statistical
significance was taken as p < 0.05 using two-tailed Stu-
dent's t-tests and chi square tests.
Results
Effect of VEGFR3-Ig fusion protein on tumor vessels and 
lymph node metastasis
Human prostate cancer cells of the PC-3 line endog-
enously express VEGF-C [9]. PC-3 cells were inoculated
into the prostates of nude mice to produce orthotopic
tumors. We and others have previously shown that they
metastasize to iliac and sacral lymph nodes [32,40]. In
order to block VEGF-C signaling, mice were injected with
recombinant adenoviruses expressing soluble VEGFR3-Ig
fusion protein (VEGFR3-Ig) that binds VEGF-C [36]. A -
galactosidase fusion protein (lacZ-Ig) was used as a con-
trol. Mice were sacrificed 4 weeks after inoculation and the
effects of VEGFR3-Ig on tumor growth, morphology, lym-
phangiogenesis, angiogenesis and metastasis to the pros-
tate-draining iliac and sacral lymph nodes and the lungs
were studied. Tumor occurrence in the prostate was 15/22
(68%) and 21/23 (91%) in the VEGFR3-Ig and lacZ-Ig
groups, respectively. The mean size of PC-3 tumors was
significantly smaller in mice injected with VEGFR3-Ig
than in lacZ-Ig-injected control mice (77 ± 6 mm3 vs. 120
± 8 mm3, respectively, p < 0.05, Fig 1A).
Histological staining (H&E) did not reveal major differ-
ences in tumor morphology (Fig 1B-C). Lymphatic vessels
were visualized using immunohistochemical staining
with m-LYVE-1 antibody and blood vessels using CD34
antibody. A moderate network of capillaries was seen in
all tumors, but treatment with VEGFR3-Ig significantly
decreased the density of both lymphatic (Fig 1D-F, 69 ±
19 m/mm2 vs. 130 ± 18 m/mm2, p < 0.05) and blood
vessels in tumors (Fig 1G-I, 24 ± 5 m/mm2 vs. 67 ± 8 m/
mm2, p < 0.05).
Histological analysis of prostate-draining lymph nodes
showed that VEGFR3-Ig treatment effectively inhibited
lymph node metastasis. The incidence of metastases at 4
weeks was 19% in the lacZ-Ig-injected tumor bearing mice
but null in the VEGFR3-Ig mice (Fig 1J-L, p < 0.001). No
metastases were found in the lungs (data not shown).
Ectopic expression of VEGF-C in PC-3 cells
In order to study the effect of VEGF-C overexpression on
tumor growth and metastasis, PC-3 cells were transfected
with a pcDNA3.1(+) vector containing the full coding
sequence for VEGF-C [9]. Several positive clones were
obtained. One clone expressing VEGF-C mRNA (data not
shown) and protein at a high level were selected for tumor
experiments (Fig 2, PC-3/VEGF-C). ELISA analysis of the
cell lysates showed difference between PC-3/VEGF-C and
PC-3/mock (0,2 ng/mL ± 0.03 in PC-3/VEGF-C cells and
0.04 ng/mL ± 0.02 in PC-3/mock cells, corresponding to
106 cells, Fig 2A). VEGF-C is a rapidly secreted protein,
and the analysis of media conditionedfor 24 h confirmed
that PC-3/VEGF-C cells secrete increased levels of VEGF-CBMC Cancer 2009, 9:362 http://www.biomedcentral.com/1471-2407/9/362
Page 5 of 12
(page number not for citation purposes)
Figure 1 (see legend on next page)BMC Cancer 2009, 9:362 http://www.biomedcentral.com/1471-2407/9/362
Page 6 of 12
(page number not for citation purposes)
protein compared with PC-3/mock (14.4 ng/mL ± 0.1 and
10.6 ng/mL ± 0.2, respectively, Fig 2B). The VEGF-C ELISA
detects all human VEGF-C forms including full-length
VEGF-C proteolytically processed forms with different
biological activities and affinities for VEGF receptors.
Western blot analysis of the conditioned medium showed
that the 29/31 kD VEGF-C polypeptides were the major
partially processed forms (Fig 2C). Small 21 kD form was
not detected.
Effect of VEGF-C on growth and metastasis of orthotopic 
and subcutaneous PC-3 tumors
To investigate tumor growth, PC-3/VEGF-C and PC-3/
mock cells were inoculated subcutaneously into the neck
or orthotopically into the prostate of nude mice. The
experiment was ended at 4 weeks. Ectopic expression of
VEGF-C increased subcutaneous tumor growth (p < 0.001
at all time points between 2 to 4 weeks, Fig 3A). At 4
weeks, the PC-3/mock tumors were small (47 ± 7 mm3)
while the PC-3/VEGF-C tumors were 24 × larger (1132 ±
34 mm3).
The occurrence of orthotopic prostate tumors was 29/33
(88%) in the PC-3/VEGF-C group and 24/28 (86%) in the
PC-3/mock group, when they were measured in the end of
the experiment. As in the subcutaneous tumors, the ortho-
topic tumors overexpressing VEGF-C were markedly big-
ger (400 ± 17 mm3 vs. 48 ± 4 mm3, p < 0.001, Fig 3B).
Effect of VEGF-C on lymphatic capillaries
The analysis of the distribution of lymphatic vessels
showed that lymphatic vessels stained for m-LYVE-1 were
located mainly in tumor periphery (Fig 4A). When the
densities of lymphatic vessels were calculated and the
Effects of adenoviral VEGFR3-Ig fusion protein on growth and metastasis of orthotopic PC-3 tumors Figure 1 (see previous page)
Effects of adenoviral VEGFR3-Ig fusion protein on growth and metastasis of orthotopic PC-3 tumors. Mice were 
treated with recombinant adenoviruses expressing the VEGFR3-Ig fusion protein (R3) or -galactosidase (lacZ). Tumor occur-
rence was 68% (n = 15/22) in the VEGFR3-Ig group and 91% (n = 21/23) in the control (lacZ-Ig) group. Blocking of VEGFR3 
decreased tumor volume compared with those in control vector treated mice (A, VEGFR3-Ig 77 ± 6 mm3, n = 15 vs. lacZ-Ig 
120 ± 8 mm3, n = 21, p < 0.05). No major differences in morphology were detected in H&E-stained sections of tumors from 
the VEGFR3-Ig (B) vs. lacZ-Ig treated mice (C). Histomorphometric analysis of tumor sections immunostained with m-LYVE-1 
antibody demonstrated that blocking of VEGFR3 decreased the density of lymphatic capillaries (D, VEGFR3-Ig 69 ± 19 m/
mm2, n = 15 vs. E and F, lacZ-Ig 130 ± 18 m/mm2, n = 21, p < 0.05). Immunohistochemical staining of tumor sections with 
CD34 antibody showed that blocking of VEGFR3 decreased the density of blood capillaries, arrows (G, VEGFR3-Ig 24 ± 5 m/
mm2, n = 15 vs. H and I, lacZ-Ig 67 ± 8 m/mm2, n = 21, p < 0.05). The incidence of metastasis (arrows) in prostate-draining 
lymph nodes was 0% (n = 0 out of 15 tumor bearing mice) in the VEGFR3-Ig group and 19% (n = 4 of 21 tumor bearing mice, p 
< 0.001) in the control group (J-L). The occurrence of metastasis in lungs was 0% in both groups (data not shown). Bar 500 m.
Ectopic expression of VEGF-C in PC-3 cells and orthotopic tumors Figure 2
Ectopic expression of VEGF-C in PC-3 cells and orthotopic tumors. PC-3 cells were stably transfected with a vector 
containing human VEGF-C (PC-3/VEGF-C) or empty vector (mock). One cell clone expressing VEGF-C at a high level, and one 
control clone (PC-3/mock) were selected for further studies. ELISA analysis of VEGF-C protein concentration in cell lysates 
(A) and in conditioned media (B) revealed increased expression in PC-3/VEGF-C cells compared with PC-3/mock cells. Data 
are expressed as means ± SD ng/mL, corresponding 106 cells. (C) Western blot analysis revealed that PC-3 cell clones 
expressed mainly 29/31 kD form of VEGF-C. Detectable levels of 21 kD form were not seen. -actin control was from cell 
lysates corresponding to the collected conditioned medium.BMC Cancer 2009, 9:362 http://www.biomedcentral.com/1471-2407/9/362
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peripheral areas of the tumors were compared, there was
no statistically significant difference between PC-3/VEGF-
C (Fig 4A) and PC-3/mock (Fig 4B) tumors. The distribu-
tion of lymphatic vessels was also studied using an anti-
body against VEGFR3. Again positive staining was seen
mainly in the peripheral areas and tumor periphery. No
statistically significant difference in distribution of
VEGFR3 positive vessels was detected between PC-3/
VEGF-C vs. PC-3/mock tumors or PC-3(VEGFR3-Ig) vs.
PC-3(lacZ-Ig) tumors (data not shown).
Increased angiogenesis in orthotopic PC-3 tumors 
expressing ectopic VEGF-C
The morphology of VEGF-C-expressing subcutaneous and
orthotopic tumors differed greatly from that of PC-3/
mock tumors. H&E staining of the PC-3/VEGF-C tumors
showed a rich network of capillary-like structures (Fig 5A
Effect of VEGF-C overexpression on PC-3 prostate tumor growth Figure 3
Effect of VEGF-C overexpression on PC-3 prostate tumor growth. The occurrence of subcutaneous tumors of both 
PC-3/VEGF-C (n = 8) and PC-3/mock (n = 12) was 100%. (A) Subcutaneous PC-3/VEGF-C tumors grew larger (1132 ± 34 
mm3, gray bars) than PC-3/mock tumors (47 ± 7 mm3, black bars) at 4 weeks and the differences in tumor volumes between 
the groups were significant at all time points between 2 and 4 weeks (p < 0.001). (B) The occurrence of orthotopical tumors 
was 88% (n = 29 out of 33 mice) in the PC-3/VEGF-C group and 86% (n = 24 out of 28 mice) in the control group. The mean 
volume of the PC-3/VEGF-C tumors was 400 ± 17 mm3 (n = 29) and in PC-3/mock tumors it was 48 ± 4 mm3 (n = 24), p < 
0.001.
Effect of ectopic VEGF-C on lymphatic vessel density of orthotopic PC-3 tumors Figure 4
Effect of ectopic VEGF-C on lymphatic vessel density of orthotopic PC-3 tumors. M-LYVE-1-positive staining was 
observed primarily in the tumor periphery and in the peritumoral area (A-B). No differences were detected in the density of 
lymphatic vessels Bar 500 m.BMC Cancer 2009, 9:362 http://www.biomedcentral.com/1471-2407/9/362
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and 5C), whereas PC-3/mock tumors were homogeneous
and solid with moderate vascular network (Fig 5B and
5D). The density of blood capillaries was studied by
means of immunohistochemical staining for CD34 (Fig
5E and 5F). Fig 5G shows that the density was indeed sig-
nificantly higher in VEGF-C overexpressing tumors com-
pared with PC-3/mock tumors (220 ± 15 m/mm2 vs. 37
± 6 m/mm2, p < 0.001). The density of VEGFR2-positive
vessels was also higher in the PC-3/VEGF-C tumors com-
pared with PC-3/mock tumors (p < 0.05) (Fig 5H, I and 5J,
30 ± 0.2 m/mm2 vs. 9 ± 0.1 m/mm2). Capillary densi-
ties were also calculated in the metastatic areas of pros-
tate-draining lymph nodes of PC-3/VEGF-C and PC-3/
mock tumors but no difference between the groups was
observed (data not shown).
Metastasis of VEGF-C-overexpressing tumors
The incidence of lymph node metastases was studied four
weeks after orthotopic inoculation of PC-3/VEGF-C and
PC-3/mock cells by histologic evaluation of H&E staining
and histomorphometry of the serially sectioned lymph
nodes. Surprisingly, metastases in iliac and sacral lymph
nodes were found only in 21% of the mice bearing PC-3/
VEGF-C tumors compared with 58% of those with PC-3/
mock tumors (p < 0.01, Fig 6). Histomorphometric anal-
ysis of lymph nodes did not show significant differences
in the relative metastatic tumor areas in iliac and sacral
lymph nodes between the groups 4 weeks after inocula-
tion of tumor cells (data not shown). Interestingly, how-
ever, histologic evaluation of the lungs showed that the
incidence of metastasis was markedly increased in the
VEGF-C-overexpressing group: 48% of mice inoculated
with PC-3/VFGF-C cells had metastases in the lungs com-
pared with 8% of the control mice (p < 0.001, Fig 6).
Effect of VEGF-C overexpression on angiogenesis of orthotopic tumors Figure 5
Effect of VEGF-C overexpression on angiogenesis of orthotopic tumors. H&E-staining of representative PC-3/VEGF-
C (A, orthotopic; C, subcutaneous) tumors and PC-3/mock (B, orthotopic; D, subcutaneous) tumors. PC-3/VEGF-C tumors 
showed angiogenic morphology with a rich network of capillaries compared with PC-3/mock tumors. There were significantly 
more blood capillaries (CD34 positive, arrows) in the PC-3/VEGF-C tumors (E, 220 ± 15 m/mm2, n = 29) compared with PC-
3/mock tumors (F and G, 37 ± 6 m/mm2, n = 24), p < 0.001. Density of VEGFR2-positive capillaries was analyzed similarly. 
Again there were significantly more VEGFR2-positive capillaries in the PC-3/VEGF-C tumors (H, 30 ± 0.3 m/mm2, n = 29) 
than in the PC-3/mock tumors (I and J, 9 ± 0.1 m/mm2, n = 24), p < 0.05. Bar 500 m.BMC Cancer 2009, 9:362 http://www.biomedcentral.com/1471-2407/9/362
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VEGFR3-Ig fusion protein treatment decreased the density 
of lymphatic capillaries
A group of mice inoculated with PC-3/VEGF-C cells was
also treated with VEGFR3-Ig fusion protein or lacZ-Ig to
study whether blockade of the VEGFR3 pathway is able to
oppose the effects of VEGF-C overexpression. As in paren-
tal PC-3 tumors treated with VEGFR3-Ig (Fig 1), the den-
sity of lymphatic capillaries was decreased in VEGFR3-Ig-
treated prostate tumors compared with lacZ-Ig-treated
(Fig 7, 23 ± 4 m/mm2vs. 123 ± 7 m/mm2, p < 0.01).
There was also a trend for a decreased number of blood
capillaries as well as decreased size in VEGFR3-Ig-treated
prostate tumors but the difference did not reach a statisti-
cal significance (data not shown).
Discussion
Expression of VEGF-C and VEGFR3 has been shown to
correlate with clinical markers such as concentration of
the circulating prostate-specific antigen (PSA) and the
Gleason score in prostate cancer [13,15]. However, it is
not clear whether VEGF-C is only a marker of progressed
disease or if it also facilitates lymph node metastasis in
prostate cancer. Experimental models suggest that VEGF-
C is involved in tumor lymphangiogenesis and often, but
not always, it is upregulated in metastatic tumors [10-
12,41-43]. According to some reports, VEGF-C-stimulated
lymphangiogenesis in tumors and lymph nodes is
required for metastasis at distant sites [44]. On the other
hand, Padera et al. [22] and Wong et al. [23] have shown
that lymph node metastasis may develop without
increased lymphangiogenesis and or even absence of
intratumoral lymphatic vessels [23].
We used orthotopic PC-3 prostate tumors that metastasize
to regional lymph nodes [32,40] to study the role of
VEGF-C in prostate tumor growth and metastasis. Block-
ade of VEGFR3 with VEGFR3-Ig decoy receptor protein led
to a decreased density of lymphatic capillaries, which was
associated with total inhibition of lymph node metastasis.
These results are in line with those of previous studies on
prostate cancer [13-15,31] and other prostate tumor mod-
els [45] suggesting that VEGF-C signaling via VEGFR3 has
a major role in lymph node metastasis. Some of the previ-
ous studies also suggest correlation between the density of
lymphatic vessel network and spreading of tumor cells to
lymph nodes, although other investigators have not
found an association between lymphatic vessel density
and lymph node metastasis [22,23,46].
In our study, the blockade of VEGFR3 by VEGFR3-Ig also
inhibited the growth of orthotopic PC-3 tumors and
Metastasis of PC-3/VEGF-C tumors to prostate-draining  lymph nodes and lungs Figure 6
Metastasis of PC-3/VEGF-C tumors to prostate-
draining lymph nodes and lungs. The prostate draining 
lymph nodes and the lungs were cut through to detect 
metastasis. Altogether 8-10 lymph nodes and six lung sec-
tions/mouse were studied and number of metastases was 
counted. The relative metastatic area of lymph nodes was 
determined by histomorphometry but there were no statisti-
cally significant differences (data not shown). The occurrence 
of metastasis in lymph nodes was 21% (n = 6 mice out of 29 
tumor-bearing mice) in the PC-3/VEGF-C group and 58% (n 
= 14 mice out of 24 tumor-bearing mice) in the PC-3/mock 
group and in lungs was 48% (n = 14 out of 29 tumor bearing 
mice) in the PC-3/VEGF-C group and 8% (n = 2 out of 24 
tumor-bearing mice) in the PC-3/mock group.
Effect of VEGFR3-Ig treatment on orthotopic PC-3/VEGF-C  tumors Figure 7
Effect of VEGFR3-Ig treatment on orthotopic PC-3/
VEGF-C tumors. VEGFR3-Ig fusion protein-producing con-
struct or lacZ-Ig controls were injected intravenously into 
mice five minutes before orthotopic inoculation of PC-3/
VEGF-C cells. The density of m-LYVE-1 positive lymphatic 
capillaries was decreased in VEGFR3-Ig-treated tumors (23 ± 
4 m/mm2, n = 8 vs. 123 ± 7 m/mm2, n = 6, p < 0.05).BMC Cancer 2009, 9:362 http://www.biomedcentral.com/1471-2407/9/362
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decreased the density of blood vessels as shown by quan-
tification of CD34-immunostained capillaries within
tumors. The VEGFR3 has been shown to contribute to the
formation of blood capillaries in various tumor models
[47], which may explain the effects on angiogenesis as
well as the decreased tumor size in orthotopic PC-3
tumors. Accordingly, orthotopic PC-3 tumors overex-
pressing ectopic VEGF-C grew much faster than mock-
transfected controls. The morphology of the tumors was
highly angiogenic as shown by histology and immunohis-
tochemical staining for CD34 and VEGFR2. This could be
explained by the fact that VEGFR3 also contributes to ang-
iogenesis as suggested in another study on PC-3 tumors
[47]. It has been shown that signaling via VEGFR3 stimu-
lates angiogenesis in developing tissues and at least in
some tumors [48]. This possibility is also supported by
our observation of decreased angiogenesis in tumors in
which VEGFR3 was blocked with VEGFR3-Ig decoy recep-
tor. Other possible explanations could be the ability of
VEGF-C to bind and activate VEGFR2, which is primarily
expressed in blood capillary endothelium [6], or stimula-
tion of angiogenic VEGFR2 by heterodimerisation of
VEGFR3 with VEGFR2 [6,49]. PC-3 cells transfected with
the VEGF-C gene almost exclusively expressed and
secreted a proteolytically processed form of VEGF-C (29/
31 kDa) that primarily binds VEGFR3 but also VEGFR2
even if with minor affinity [6].
Analysis of the distribution of the lymphatic capillaries
showed that there was no statistically significant differ-
ence in the density of lymphatic capillaries in tumor
periphery between PC-3/VEGF-C and PC-3/mock tumors.
However, it seemed that the center of PC-3/VEGF-C
tumors had fewer lymphatic vessels than PC-3/mock and
PC-3 tumors. Other investigators have reported that
tumor center lacks functional lymphatic vessels [22,23] or
that it is primarily the peripheral lymphatic capillaries
that mediate tumor cell spread to lymph nodes [23].
Many studies have also reported an increased network of
peritumoral lymphatic vessels in experimental breast and
prostate tumors [10-20]. It has been claimed that elevated
interstitial fluid pressure within the tumors may compress
thin-walled lymphatic capillaries and compromise their
function [50]. In our experiments it seemed likely that the
highly expanded network of blood vessels in PC-3/VEGF-
C tumors may have caused pressure that has impaired or
prevented growth of lymphatic capillaries within the
tumor tissue. This may also have caused decreased metas-
tasis to lymph nodes. However, our observation that the
presence of peritumoral lymph vessel network similar to
that in control tumors was associated with decreased
lymph node metastasis. This suggests that also the central
vessels play a role in lymphatic tumor spread or that other
metastatic routes were primarily used in PC-3/VEGF-C
tumors.
Interestingly, while high expression of VEGF-C in ortho-
topic PC-3 tumors was associated with decreased lymph
node metastasis, the rate of lung metastasis was clearly
increased. Even wild-type PC-3 tumors metastasize to the
lungs, but at a low rate and slowly along an extended time
period whereas in PC-3/VEGF-C tumor-bearing mice
metastasis to the lungs was increased or at least clearly
accelerated. In our experiments it seems possible that in
these tumors, lung metastases arose via hematogenous
pathways, facilitated by the extensive blood capillary net-
work. Another possibility is that the tumor cells spreading
via lymphatic vessels passed the lymph nodes and were
taken to distant sites. Burton et al. [21] very recently
reported that in different orthotopic prostate cancer mod-
els VEGF-C/VEGFR3 mediated metastasis to lymph nodes
was mandatory to metastasis to distant sites. In addition,
Hirakawa et al. [44] have recently shown evidence that
VEGF-C can facilitate tumor cell metastasis to lung and
other organs by modulating lymph node vascularization
and function. If this was the case in our PC-3/VEGF-C
tumor-bearing mice, the reasonably dense network of per-
itumoral lymphatic vessels would have mediated the
spread of the tumor cells to distant sites via lymph nodes
to the lungs. It will be interesting to investigate in further
studies the possible effect of VEGF-C on tumor cell sur-
vival outside the tumor environment and on the interac-
tions of tumor cells with lymphoid tissues and cells at
other metastatic sites.
Our observations on a switch of a lymphangiogenic to an
angiogenic-type pattern of metastasis upon high VEGF-C
expression in prostate cancer models differ from the
results of some other studies [20,21]. Those studies
reported that VEGF-C/VEGFR3 stimulation primarily
increased lymphatic vessel network and lymph node
metastasis, which was also a prerequisite for later lung
metastasis if it was observed. The reason for this discrep-
ancy is presently unclear but one explanation in our
tumors could be a expanded blood capillary network,
which may have provided a more effective pathway for
metastasis than lymphatic capillaries. It is obvious, how-
ever, that the regulation of metastatic pathways by differ-
ent factors is very versatile and context dependent in
various tumor models [23,48].
Treatment of PC-3/VEGF-C tumor bearing mice with
VEGFR3-Ig further decreased the density of lymph vessels.
This suggests that the formation of new lymphatic capil-
laries in PC-3 tumors is dependent on VEGFR3 function
even in the presence of massive angiogenesis. Treatment
with VEGFR3-Ig had, however, less obvious effects on
CD34-positive blood capillary density and tumor size
than in parental PC-3 tumors. The reason for this differ-
ence is presently unclear but it is possible that the
VEGFR3-Ig treatment conditions (concentrations, dosingBMC Cancer 2009, 9:362 http://www.biomedcentral.com/1471-2407/9/362
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schedule) should have been further scrutinized to obtain
an optimal inhibition of all effects of VEGF-C overexpres-
sion.
Conclusion
Our results show that although the VEGF-C/VEGFR3
pathway is important for formation of lymphatic vessels
and lymph node metastasis of orthotopic PC-3 prostate
tumors, high expression level of VEGF-C can also lead to
activation of angiogenesis. This is associated with a
change in the pattern of primary lymph node metastasis
to preferential occurrence of metastasis at distant sites
such as the lung, which suggests that the hematogenous
route is preferred over the lymphatic route as a metastatic
pathway of the orthotopic prostate tumors. Our results
support the concept that the development of angiogenic
and lymphangiogenic metastatic routes is tumor and con-
text dependent. An effective blockade of both lymphang-
iogenic and hematogenous pathways is thus needed to
inhibit metastasis in prostate cancer.
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